Claris Biotherapeutics develops biologic therapies for corneal diseases and other disorders affecting the ocular surface.
Claris Biotherapeutics has raised $118.0M in total funding. The most recent round was Series B. The last funding was announced in July 2026.
Claris Biotherapeutics's investors include RA Capital Management, Catalio Capital Management, Janus Henderson Investors, Samsara BioCapital, Novo Holdings.
Claris Biotherapeutics is headquartered in Jersey City, United States.
Claris Biotherapeutics develops biologic therapies for corneal diseases and other disorders affecting the ocular surface.
Claris Biotherapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Claris Biotherapeutics — Funding & Investors." VCBacked, July 28, 2026, https://www.vcbacked.co/company/claris-biotherapeutics. Accessed October 29, 2026.
VCBacked. (2026). Claris Biotherapeutics — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/claris-biotherapeutics
{{cite web |title=Claris Biotherapeutics — Funding & Investors |url=https://www.vcbacked.co/company/claris-biotherapeutics |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated